OS Therapies' OSAH Subsidiary Receives U.S. Department Of Agriculture Guidance On Commercial Deployment Pathway For OST-HER2 To Treat Canine Osteosarcoma

OS Therapies, Inc. (NYSE: OSTX) announced that its subsidiary OSAH has received guidance from the U.S. Department of Agriculture regarding the commercial development pathway for OST-HER2, aimed at treating canine osteosarcoma. The USDA's feedback pertains to OSAH's upcoming conditional licensure request, focusing on clinical efficacy, safety, and manufacturing controls as part of the pre-commercialization process.